Patients in England with HER2-low metastatic breast cancer can now access Enhertu on the NHS, a drug that can extend life by nearly seven months on average. This approval comes after a lengthy campaign from patients and charities, highlighting the emotional toll of waiting for treatment. While Scotland has offered Enhertu since 2023, the delay in England has meant that many women missed out on this potentially life-saving medication.
The decision to approve Enhertu is significant not just for patients but also reflects changes in how the NHS evaluates drug costs. The National Institute for Health and Care Excellence (NICE) has adjusted its threshold for what it considers a reasonable cost per Quality-Adjusted Life Year (QALY), increasing it from £30,000 to £35,000. This shift, influenced by a trade deal with the USA, allows for more treatments to be considered viable, potentially changing the landscape of NHS drug approvals.
However, the bittersweet nature of this announcement is palpable among patients and advocates. Many have fought tirelessly for access, and while this victory is celebrated, it serves as a reminder of those who have lost their lives waiting for treatments like Enhertu. The emotional weight of this decision is felt deeply, as families and friends reflect on the lives that could have been saved with timely access.
Looking ahead, this case underscores the need for a more responsive healthcare system. Advocates are calling for collaboration among government bodies, NICE, and pharmaceutical companies to ensure that patients do not have to endure lengthy waits for critical treatments. The hope is that Enhertu’s approval will pave the way for faster access to other life-extending drugs in the future.
Source: BBC News
